close 74% of retail accounts lose money when trading CFDs with this provider. Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 74% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
SearchSearch
Change languageEnglish (International)
Dashboard

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Home・Stock List・VIRIDIAN THERAPEUTICS INC
Search

VIRIDIAN THERAPEUTICS INC

Closed

SectorHealthcare

12.54 -3.98

Strong Buy

Price update 3 Apr 2025, 19:59 UTC

BuySell

Overview

Share price change

24h

Current

Min

11.82

Max

13.05

Key metrics

By Trading Economics

Income

-3M

-80M

Sales

-14K

72K

EPS

-0.81

Profit margin

-110,729.167

Employees

143

EBITDA

-3.2M

-79M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+214.54% upside

Dividends

By Dow Jones

Next Earnings

7 May 2025

Market Stats

By TradingEconomics

Market Cap

9.5M

1.2B

Previous open

16.52

Previous close

12.54

News Sentiment

By Acuity

50%

50%

180 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

12.53 / 15.43 Support & Resistance

VIRIDIAN THERAPEUTICS INC Chart

Past performance is not a reliable indicator of future results.

Related News

10 Sept 2024, 20:38 UTC

Acquisitions, Mergers, Takeovers

How This Amgen Rival Is Taking On The Company's $28 Billion Acquisition -- IBD

DJ

Read

10 Sept 2024, 14:42 UTC

Acquisitions, Mergers, Takeovers

How This Amgen Rival Is Taking On The Company's $28 Billion Acquisition -- IBD

DJ

Read

Peer Comparison

Price change

VIRIDIAN THERAPEUTICS INC Forecast

Price Target

By TipRanks

214.54% upside

12 Months Forecast

Average 41.11 USD  214.54%

High 50 USD

Low 27 USD

Based on 10 Wall Street analysts offering 12 month price targets forVIRIDIAN THERAPEUTICS INC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

9

Buy

1

Hold

0

Sell

Based on 10 analysts giving stock ratings to VIRIDIAN THERAPEUTICS INC - Dist in the past 3 months.

Technical Score

By Trading Central

12.53 / 15.43Support & Resistance

Short Term

Strong Bearish Evidence

Bearish events outweigh bullish events.

Intermediate Term

Bearish Evidence

Bearish events outweigh bullish events.

Long Term

Strong Bearish Evidence

All events are bearish.

Sentiment

By Acuity

180 / 386 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

Other stocks from the sector

MDT

Medtronic PLC

87.86

↓-1.21%

VEEV

Veeva Systems Inc

221.66

↓-2.12%

A

Agilent Technologies Inc

109.71

↓-5.41%

HQY

HealthEquity Inc

82.88

↓-6.59%

PDCO

Patterson Cos Inc

31.2

↓-0.22%